With decades of combined experience in bioinformatics, immunology, and oncology, our team possesses the expertise and knowledge necessary for accurate identification of immunogenic mutations, enabling us to effectively target these as neoantigens in the field of cancer vaccine development.
Lykeion is a clinical-stage biopharma company focused on cancer vaccine development, dedicated to designing and delivering personalized cancer vaccines for all patients. This approach is based on a deep understanding of immunogenic mutations and the individual's tumor targets, as well as their natural immune response.
We have developed a novel platform that identifies neoantigens associated with various cancer types, contributing to advancements in cancer vaccine development. Our powerful vaccine approach harnesses the patient's own immunity, facilitating a broad and coordinated attack on their tumor by targeting immunogenic mutations.